The Opportunity at DiscGenics Compared to Prior Ventures I’ve Encountered

I am absolutely inspired by the opportunity that dysgenics presents. I have been involved in the surgical device industry for a while, but this is different. This is an opportunity to serve a much larger patient population with a significantly higher impact. It is estimated that 250 million patients globally are affected by disc degeneration annually, making it the number one reason for disability worldwide and the second biggest reason people visit a doctor. In the U.S alone, over a hundred billion dollars are spent on it.

What's even more exciting is that we believe we can help these patients in the least invasive way possible - through injections. Our recent human trial results show that patients experience a dramatic reduction in pain and disability, along with a noticeable improvement in their quality of life within just 12 weeks of treatment. The results have been durable and have lasted up to two years.

This is different from other cell therapies that have been developed for smaller patient populations for orphan issues and genetic problems. Our Cell Therapy has the potential to disrupt surgery and be a game-changer in the Spine Care industry. The notion of restoring function and possibly resolving the degeneration altogether is truly exciting. It is a chance to positively impact the lives of a very large patient population and change the paradigm of spine care.